Related Experiment Video
Updated: Apr 28, 2026
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Patterns of Disease Progression in Advanced Breast Cancer Patients Treated With Cyclin D Kinase 4/6 Inhibitors:
Sudhir Kumar1, Neha Pathak2, Rossanna C Pezo1
1Division of Medical Oncology and Hematology, Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada; Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
Introduction:
To study the patterns of progression (POP) in hormone receptor-positive (HR+), human epidermal growth receptor 2-negative (HER2-) advanced breast cancer (aBC) treated with cyclin D kinase inhibitor (CDK 4/6i) and analyze their impact on prognosis and subsequent treatment.
Patients And Methods:
We retrospectively investigated patients with HR+ HER2- aBC with progressive disease after CDK4/6i treatment at our center from 2016 to 2020. Based on European Society for Radiotherapy and Oncology (ESTRO)/European Organization for Research and Treatment of Cancer (EORTC) consensus, patients were divided into 4 groups: repeat oligoprogression (RO, oligoprogression with a history of oligometastatic disease), induced oligoprogression (IO, oligoprogression with a history of polymetastatic disease), collectively oligoprogressive disease (OPD), de novo polyprogression (DP, polyprogression with a history of oligometastatic disease), and repeat polyprogression (RP, polyprogression with a history of polymetastatic disease)-together diffusely progressive disease (DPD). Kaplan-Meier survival analysis was used for time-to-event data.
Results:
Among the 151 patients, 47 (31%) had OPD, including 33 (22%) with RO and 13 (9%) with IO. Similarly, 104 (69%) patients had DPD, including 93 (61%) with RP and 12 (8%) with DP. The 1-year next-line progression-free survival (nPFS) was 60.5% in the IO group, 42.9% in the RO group, 30.3% in the DP group, and 26% in the RP group (P = .01). The 3-year overall survival (OS) was also significantly different (84% vs. 79% vs. 66% vs. 39%, P = .02). The continuation of CDK4/6i beyond oligoprogression did not lead to worse outcomes (6-month nPFS, 69.9% vs. 73.7%, P = .07).
Conclusion:
The 4 distinct POP after CDK 4/6i treatment have prognostic value, and in this small but relevant cohort of patients, continuation of CDK 4/6i appears to be safe in those with IO.
More Related Videos
06:00Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
08:48An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation
Published on: June 30, 2015
Related Concept Videos
02:34Inhibition of Cdk Activity
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
02:15M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
02:39Positive Regulator Molecules
01:45Positive Regulator Molecules
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...